PGA treatment success: PGA score of 0 or 1 and ≥2-grade improvement from baseline to week 12 (ITT, MI)2,5-7
36% and 40% of patients achieved treatment success in the VTAMA cream arms vs 6% and 6% in the vehicle arms in PSOARING 1 and 2.2
PASI75 from baseline to week 12 (ITT, MI)5,8
VTAMA cream delivered significant PASI75 rates as early as week 4 and at week 12, up to 48% of patients achieved PASI75 vs ~10% of those using vehicle.
ITT, intention-to-treat; MI, multiple imputation; PASI75, ≥75% improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment.
See the significant results from patients in VTAMA cream pivotal studies. VTAMA cream helped adult patients with mild, moderate, and severe plaque psoriasis achieve clearer skin. Please note that the photographs you will see are representative of one target lesion on individual patients treated with VTAMA cream during the pivotal clinical studies.
Age: 56 Gender: Female Patient: 1017-010
Primary Endpoint Success*9
Baseline
Week 4
Week 12
Age: 26 Gender: Male Patient: 2903-005
Primary Endpoint Failure*9
Baseline
Week 4
Week 12
Age: 67 Gender: Male Patient: 2030-001
Primary Endpoint Failure*9
Baseline
Week 4
Week 12
Age: 48 Gender: Male Patient: 1015-007
Primary Endpoint Success*9
Baseline
Week 4
Week 12
Age: 63 Gender: Male Patient: 2014-011
Primary Endpoint Success*9
Baseline
Week 4
Week 12
DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PP-NRS, Patient-Reported Peak Pruritus Numeric Rating Scale.
*Regulatory success refers to the primary study endpoint of a patient reaching a PGA score of 0 or 1 and a ≥2-grade improvement at week 12.
†PGA and PASI are global efficacy assessments. Example of 1 representative target lesion of 1 VTAMA cream–treated patient from the PSOARING clinical studies.
‡PASI was measured as a secondary endpoint.
§DLQI and PP-NRS are Patient-Reported Outcomes.
Significantly improved as early as week 2 and maintained through week 12, with up to ~68% of VTAMA cream patients achieving a minimum 4-point improvement in PP-NRS* vs 46% on vehicle at week 12. PP-NRS data was a prospective Patient-Reported Outcome secondary endpoint.10
ITT, intention-to-treat; OC, observed cases.
*Peak Pruritus Numeric Rating Scale (PP-NRS), patient self-reported item. PP-NRS is an 11-point scale ranging from “no itch” (0) to “worst itch possible” (10), to assess worst itch experienced in a 24-hour period.11
†In those patients with at least a 4-point Peak Pruritus NRS at baseline.
‡Denotes statistical significance.
Remittive effect is continued efficacy while on treatment and lasting results even when off-treatment as demonstrated in the 40-week, open-label, long-term extension study (LTE).3
Not actual patients
Patients (n=73) who entered the open-label LTE with clear skin (PGA=0) maintained clear or almost clear skin (PGA=0 or 1) for a median time of 114 days2
Of the patients (n=519) entering the open-label LTE with PGA≥2, 58.2% achieved PGA=0 or 1 at least once during the open-label LTE3
No evidence of tachyphylaxis3
PSOARING 3 was an open-label, long-term extension study (LTE) designed to evaluate safety, durability of response, and duration of remittive effect (median time to PGA≥2 from PGA=0) of VTAMA cream over 40 weeks.3
763 patients enrolled
At the end of the 12-week pivotal studies, 763 patients (92% of eligible patients) rolled over to the open-label LTE2,3
Clear skin
41% of patients (n=312) achieved PGA=0 at least once during the open‑label LTE and had a mean total duration of disease control (PGA=0 or 1) of ~4 months3
~4 Months off-treatment
Patients (n=73) entering the open‑label LTE with clear skin (PGA=0) maintained clear or almost clear skin (PGA=0 or 1) for a median time of 114 days2
Sign up today to get the latest around VTAMA (tapinarof) cream, 1%, and other helpful tips and information.
*Required field
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
 Strictly Necessary Cookies
|
Always active |
|
Performance Cookies
|
|
|
Targeting Cookies
|
Robert, 36
Not an actual patient
Your adventurous patient
• Concerned about plaque psoriasis flare-ups limiting his active lifestyle. During a flare-up, his affected BSA can go up to 5% and his PGA score is 3 (moderate)
• Wants something to help keep his psoriasis plaques clearer so he doesn’t have to worry about them
Previous
Emily, 51
Not an actual patient
Your active and public‑facing patient
• Works in a public-facing job and is self-conscious about her appearance when having a plaque psoriasis flare
• Has mild plaque psoriasis and is not a candidate for biologics
• Cycled through different over-the-counter steroid creams, which did not give her the results she was looking for
• Does a lot of research but relies on her dermatologist for her best options
Previous
Carlos, 55
Not an actual patient
Your patient with sensitive skin
• Has an affected BSA of 10%, and psoriasis plaques are concentrated in sensitive areas
• Has psoriasis plaques on sensitive areas of his body, including his genitals, causing embarrassment
• Felt topical corticosteroids were not the right option for him due to his treatment area
• Wants to get back to socializing and dating without worrying about psoriasis plaques
Previous
